The epithelial-mesenchymal transition (EMT) is the pivotal mechanism underlying the initiation of cancer invasion and metastasis. Although Mel-18 has been implicated in several biological processes in cancer, its function in the EMT of human cancers has not yet been studied. Here, we demonstrate that Mel-18 negatively regulates the EMT by epigenetically modulating miR-205. We identified miR-205 as a novel target of Mel-18 using a microRNA microarray analysis and found that Mel-18 increased miR-205 transcription by the inhibition of DNA methyltransferase-mediated DNA methylation of the miR-205 promoter, thereby downregulating its target genes, ZEB1 and ZEB2. Furthermore, the loss of Mel-18 promoted ZEB1-and ZEB2-mediated downregulation of E-cadherin transcription and also enhanced the expression of mesenchymal markers, leading to increased migration and invasion in MCF-7 cells. In MDA-MB-231 cells, Mel-18 overexpression restored E-cadherin expression, resulting in reduced migration and invasion. These effects were reversed by miR-205 overexpression or inhibition. A tumor xenograft with Mel-18 knockdown MCF-7 cells consistently showed increased ZEB1 and ZEB2 expression and decreased E-cadherin expression. Taken together, these results suggest that Mel-18 functions as a tumor suppressor by its novel negative control of the EMT, achieved through regulating the expression of miR-205 and its target genes, ZEB1 and ZEB2.
INTRODUCTION
The epithelial-mesenchymal transition (EMT) is a developmental process in which epithelial cells lose their polarity and acquire the migratory properties of mesenchymal cells. 1 The EMT is known to be a central mechanism responsible for the invasiveness and metastasis of various cancers, and the induction of the EMT generates cancer-initiating cells with stem-like properties. [2] [3] [4] A key step in the EMT is the downregulation of E-cadherin, which is most notably suppressed by Snail-related zinc-finger transcriptional repressors (Snail and Slug) as well as by SIP-1/ZEB-2, DEF-1/ZEB-1 and the bHLH transcription factors Twist and E12/E47. 5 Recently, epigenetic reprogramming has been found to be involved in the EMT of human cancer cells. 6 In particular, histone and DNA methylation and modification of chromatin structure within the E-cadherin promoter has been reported. 7, 8 MicroRNAs (miRNAs) are small non-coding RNA molecules that can regulate gene expression by interacting with multiple mRNAs to either suppress the translation of, or degrade, the molecules. 9 Accumulating studies have described the important role of miRNAs in the pathogenesis and development of human cancers including breast cancer. [10] [11] [12] Several miRNAs, such as the members of the miR-200 family and miR-205, influence tumor invasion and metastasis by directly targeting the E-cadherin transcriptional repressors ZEB1 and ZEB2. 9, 13 miRNAs also are involved in the epigenetic control of biological processes through a complicated network of reciprocal interconnections and directly connect to the epigenetic machinery through a regulation loop. 14 Polycomb group (PcG) proteins are chromatin-modifying proteins that have a crucial role in many biological processes, including differentiation and tumorigenesis. 15 Overexpression of certain PcG proteins, such as Bmi-1 and EZH2, has been linked to invasive breast and prostate cancer. 16, 17 Recent studies have found that the repression of E-cadherin expression by Bmi-1 is essential for the Twist-induced EMT of cancer cells. 18 Moreover, Bmi-1 is negatively regulated by the miR-200 family. 19 Mel-18, a homolog of Bmi-1 and a putative constituent of polycomb repressive complex-1 (PRC-1), interacts with Bmi-1 20, 21 and functions as a tumor suppressor and a transcriptional repressor of Bmi-1 expression in human cells. 22, 23 Our recent studies have shown that Mel-18 inhibits cell proliferation and angiogenesis in breast cancer. 23, 24 However, the role of Mel-18 in the EMT of tumor progression, particularly in processes such as invasion and metastasis, has not been evaluated.
In this study, we found that Mel-18 negatively regulates the EMT of breast cancer through miR-205-mediated ZEB1 and ZEB downregulation. Furthermore, Mel-18 epigenetically modulates miR-205 expression by controlling DNA methylation of the miR-205 promoter region. These results support that Mel-18 suppresses tumor function by negatively regulating the EMT and may be a crucial regulator of breast cancer progression.
RESULTS

Mel-18 inhibits ZEB1 and ZEB2 expression by targeting miR-205
Recently, polycomb proteins such as EZH2 and Bmi-1 have been found to modulate several miRNAs. 25 To discover miRNAs regulated by Mel-18, we established Mel-18 knockdown MCF-7 (MCF-7 shMel ) cell lines using lentiviral short hairpin RNAs and investigated miRNAs expression with an Agilent Human MicroRNA Microarray. The expressions of several miRNAs were statistically significantly downregulated in MCF-7 shMel cells compared with control cells (Po0.05, paired t-test; Figure 1a and Supplementary Table 1) , and these miRNAs were involved in many biological processes (Supplementary Table 2 ). In particular, we noted the decreased expression of miR-205 in MCF-7 shMel because miR-205 is known to regulate ZEB1 and ZEB2 expression, leading to repression of the EMT. 26 To find the relationship between Mel-18, miR-205 and these EMT markers, their protein and RNA levels were measured by immunoblotting and reverse transcription-PCR in several breast cancer cell lines. Mel-18 expression was relatively higher in noninvasive and epithelial-like breast cancer cells such as MCF-7 than in invasive breast cancer cells including MDA-MB-231 cells (Supplementary Figure 1a) . Moreover, Mel-18 expression was positively correlated with E-cadherin and miR-205 expression and negatively associated with ZEB1 and ZEB2 in these cell lines ( Supplementary Figures 1a and b) Figure 1b) . We also validated the expression of other putative Mel-18-target miRNAs, miR-23b, miR-144, and miR-215, which have potential binding site for ZEB1 or ZEB2 gene predicted by TargetScan and found that these three miRNAs were downregulated by Mel-18 knockdown and upregulated by Mel-18 overexpression (Supplementary Figure 2) . However, their expression change by Mel-18 was not as significant as miR-205. We next examined whether ZEB1 and ZEB2 are targeted by miR-205 in Mel-18 knockdown or overexpressing stable cell lines. The activity of luciferase reporter constructs of the 3 0 untranslated regions (UTRs) of ZEB1 and ZEB2, which contain the binding sites of several miRNAs including miR-205, was positively regulated by Mel-18 (Figures 1c  and d) . Furthermore, these activities were reduced by treatment with a synthetic miRNA mimic in MCF-7 shMel cells and increased by antago-miR-205 treatment in MDA231 Mel-18 cells, indicating that Mel-18 induced the binding of miR-205 to ZEB1 and ZEB2 (Figure 1e ). Transient Mel-18 knockdown by siRNA or Mel-18 overexpression also showed a similar effect on the activity of ZEB1 and ZEB2 3 0 UTRs ( Supplementary Figures 3a and b) Figures 3c and d) 
Mel-18 suppresses EMT and invasion in breast cancer by targeting miR-205
We next examined the effect of Mel-18 on EMT progression after the induction of EMT by transforming growth factor (TGF)-b1, as Mel-18 modulated the expression of miR-205, which is a potential regulator of EMT. MCF-7 shMel cells had a mesenchymal-like morphology, including a greater number of spindles (Figure 3a,  left) . Moreover, the expression of the epithelial markers E-cadherin and b-catenin was reduced, whereas the expression of the mesenchymal markers Snail, ZEB1, ZEB2, N-cadherin, vimentin and fibronectin was increased in these cells (Figure 3b, left) . Consistent with these observations, Mel-18 overexpressing cells exhibited an epithelial-like morphology, upregulation of the expression of epithelial markers and downregulation of the expression of mesenchymal markers (Figure 3a , middle and right, and Figure 3b , right). The reduction of E-cadherin and induction of mesenchymal markers including ZEB1 were also confirmed by confocal microscopy in MCF-7 shMel cells (Figure 3c ). We next examined whether Mel-18 affected the migration and invasion of breast cancer cells bya an EMT-like phenotype change. TGF-b1 treatment triggered increased migration and invasion in MCF-7 shMel cells, whereas this activity was decreased in MDA231- and SK-BR-3 Mel-18 cells (Figures 3d and e) . Mel-18 regulates E-cadherin expression by inhibiting ZEB1 and ZEB2 As ZEB1 and ZEB2 can repress E-cadherin transcription via direct binding to the E-box motif in the E-cadherin promoter, 5 we investigated the effect of Mel-18 on E-cadherin transcription activity and the binding ability of ZEB1 and ZEB2 to the E-cadherin promoter after TGF-b1 treatment. Using a luciferase reporter assay, we found that Mel-18 knockdown decreased E-cadherin promoter activity; this effect was abolished in the E-box mutant E-cadherin promoter in MCF-7 cells (Figure 5a, left) . MDA231 showed enhanced E-box-dependent E-cadherin promoter activity (Figure 5a, right) . Moreover, the binding of ZEB1 and ZEB2 to the E-cadherin promoter was enhanced in MCF-7 shMel cells but was blocked in MDA231 Mel-18 cells (Figure 5b ). These binding abilities were dependent on miR-205 expression as measured by ChIP assay of E-cadherin promoter after treatment of pre-miRNA or antago-miRNA (Figure 5c ). In addition, E-cadherin downregulation was rescued by inhibition of ZEB1 and ZEB2 expression using siRNA in MCF-7 shMel cells (Figure 5d ). Therefore, these results indicate that Mel-18 inhibits the binding of ZEB1 and ZEB2 to the E-box motif in the E-cadherin promoter and enhances E-cadherin expression. Our result was confirmed in vivo in a tumor xenograft mice model. Immunohistochemistry analyses of tumors xenografted with MCF-7 shMel cells showed that ZEB1 and ZEB2 expression increased, whereas E-cadherin expression decreased (Figure 5e ). Taken together, these data indicate that Mel-18 is a positive regulator of E-cadherin via downregulation of the E-cadherin repressors ZEB1 and ZEB2.
DISCUSSION
We demonstrated that Mel-18 negatively regulates the EMT by modulating the miR-205/ZEB1-ZEB2/E-cadherin cascade. We showed that loss of Mel-18 decreases miR-205 expression by inhibiting DNMT family-mediated DNA methylation of the miR-205 promoter. The reduction of miR-205 led to increased ZEB1 and ZEB2 expression and the subsequent downregulation of E-cadherin transcription, thereby enhancing the TGF-b1-induced EMT and invasion of breast cancer cells ( Figure 6 ). These data are the first to demonstrate a miR-205-dependent EMT regulatory mechanism controlled by the PcG protein Mel-18 in breast cancer.
Mel-18 has been proposed to have a tumor-suppressive function in breast cancer. In accordance with this suggestion, our findings show that the depletion of Mel-18 enhances the EMT, which is important for tumor progression and particularly for the processes of invasion and metastasis. Recently, we showed that Mel-18 negatively regulates tumor angiogenesis by inhibiting PI3K/Akt-mediated HIF-1a stability and vascular endothelial growth factor (VEGF) expression. 24 There is much evidence supporting a link between angiogenesis and the EMT. Several angiogenic factors including VEGF and VEGF receptor and their regulator, HIF-1a, are involved in EMT induction by modulating the expression and activity of EMT-associated transcription factors, such as Snail, Twist and Slug. [28] [29] [30] TGF-b is crucial for the stimulation of both angiogenesis and the EMT. 31 Together with our previous report, 24 our data indicate that Mel-18 can modulate both the EMT and angiogenesis, which are crucial for tumor progression and aggressiveness. Furthermore, we suggest that Mel-18 might participate in TGF-b1 signaling, because our data show that the loss of Mel-18 promotes TGF-b1-induced EMT by ZEB1 and ZEB2 expression and subsequent E-cadherin downregulation. Some reports suggest that PcG proteins have a role in TGFb1-induced EMT. TGF-b1 activates repressors related to hairy/ enhancer-of-split via Smad3/4, which in turn repress EZH1 and EZH2 genes during EMT. 7 Slug, a dominant regulator of TGF-b1-induced EMT, and polycomb bind to Klf4 and Foxa1, leading to the inhibition of epithelial features. 32 PcG proteins including Mel-18 and EZH2 may therefore have critical functions in the EMT via diverse molecular mechanisms.
Recently, the EMT was shown to generate cells with stem celllike properties, highlighting its emerging role in the regulation of cancer stem cells (CSCs). 3, 4 EMT inducers such as TGF-b and Wnt cause cells to acquire a CD44 high /CD24 low phenotype, representing a subpopulation of breast CSCs. 33 Moreover, EMT-related transcription factors have been found to be involved in the regulation of self-renewal of CSCs. For instance, Twist, a key player in the EMT, and Bmi-1, a PcG protein involved in self-renewal, are mutually essential for promoting the EMT and for tumor initiation. 5, 18 They act cooperatively to repress the expression of both E-cadherin and p16INK4a. 18 Previously, we reported that Mel-18 negatively regulates Bmi-1 expression. Indeed, our preliminary data show that Mel-18 inhibits the accumulation of breast CSCs and their self-renewal, as well as in vivo tumor initiation (unpublished data). These results suggest that Mel-18 might be important for EMT-induced CSCs and that the loss of Mel-18 may contribute to the aggressiveness of breast cancer through the induction of the EMT.
Here, we found that depletion of Mel-18 is correlated with the loss of miR-205, a key regulator of the EMT process via modulation of ZEB1 and ZEB2 expression. This suggests that miRNAs have a crucial role in the regulation of breast cancer by Recently, many miRNAs have been found to have a critical role in human cancer development. Moreover, it is likely that PcG proteins modulate many biological processes in human cancer through miRNAs. For example, EZH2 may control miRNAs involved in cancer cell growth, invasion, metastasis and stem cell regulation. 25, 34 Polycomb-mediated miR-31 downregulation initiates nuclear factor-kB signal activation in some cancers including leukemia. 35 Our data indicate that Mel-18 has a novel role in miRNA-mediated tumor progression, especially in relation to the EMT. Two miR-205 sites have been found in the ZEB2 3 0 UTR, along with three miR-200a sites and six miR-200b sites. 26 The importance of the miR-205/Mel-18 system for the control of ZEB1 and ZEB2 expression in breast cancer cells is notable because the 3 0 UTRs of ZEB1 and ZEB2 contain many more binding sites for the miR-200 family than for miR-205. Furthermore, normal human mammary glands show miR-205 expression in the ductal and lobular myoepithelial/basal compartments. 36 Collectively, we propose that miR-205 regulation by Mel-18 is crucial for the EMT and tumor invasion in breast cancer.
Interestingly, our data indicate that Mel-18 controls miR-205 expression via DNA methylation of its promoter. It has been shown that the expression of miRNAs is regulated by several epigenetic mechanisms including DNA methylation and histone modification, and that the alteration of the miRNA expression level by these changes is an important signature of tumor progression in a variety of cancers. 37 During the transformation of human lung epithelial cells, several tumor-suppressive miRNAs containing miR-205 are epigenetically silenced by DNA methylation, triggering EMT induction. 13 Our data also show that miR-205 expression is modulated by DNA methylation in human breast cancer cells, with Mel-18 functioning as a novel regulator of DNA methylation in the miR-205 promoter region. PcG proteins have a crucial role in the maintenance of DNA methylation by regulating the DNMT family. For example, EZH2, a PRC-2 protein, directly interacts with DNMTs and enhances their DNMT activity. 38, 39 Among the PRC-1 proteins, CBX proteins and Bmi-1 have been linked to the regulation of DNMT activity. 40, 41 Unlike other PcG proteins, however, Mel-18 appears to negatively regulate DNA methylation. We found that Mel-18 facilitates the disassociation of DNMTs from the target gene promoter and consequently inhibits DNA methylation. It is possible that Mel-18 indirectly inhibits DNA methylation by downregulating Bmi-1 expression, as has been shown in breast cancer. 23, 42 Mel-18 also negatively regulates Bmi-1-dependent RING1b ubiquitin E3 ligase activity. 43 Future studies should examine whether Mel-18 controls Bmi-1-dependent DNMT activity or directly associates with DNMTs to inhibit their activity. Interestingly, Mel-18 may increase the miR-205 expression level without changing the DNA methylation pattern and miR-205 promoter activity in MDA-MB-231 cells, which have a highly methylated miR-205 promoter. These data imply that Mel-18 might also be involved in posttranscriptional regulation of miRNA biogenesis as well as epigenetic control of miRNA transcription, and support the crucial role of Mel-18 in the epigenetic regulation of miRNAs and miRNA-mediated cancer progression through the inhibition of DNA methylation.
In conclusion, our findings provide evidence for the tumorsuppressive role of Mel-18 in the EMT. We propose that Mel-18, as an epigenetic regulator of miR-205 through the control of DNA methylation, inhibits the EMT and tumor invasion and also may be involved in EMT-induced cancer stemness and metastasis. Thus, loss of Mel-18 might be a critical step in tumorigenesis in breast cancer.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer cell lines were obtained from American Type Culture Collection and cultured in Dulbecco's Modified Eagle's Medium (DMEM) without phenol red (Welgene, Daegu, Republic of Korea), containing 10% fetal bovine serum. MCF10A cells were maintained in DMEM/F12 medium (Welgene) supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 10 mg/ml insulin and 0.5 mg/ml hydrocortisone. 5-Aza-2 0 -deoxycytidine and Trichostatin A were obtained from Sigma-Aldrich (St Louis, MO, USA). TGF-b1 was purchased from R&D Systems (Minneapolis, MN, USA).
Virus infection, siRNA transfection
To generate Mel-18 knockdown or overexpressing cell lines, lentiviruses encoding control short hairpin RNA or Mel-18 short hairpin RNA and retroviruses encoding empty vector or Mel-18 cDNA were transduced into target cells as previously described. 23, 24 For transient knockdown of DNMT1, ZEB1 and ZEB2, non-targeting siRNA and siRNAs for DNMT1, ZEB1 and ZEB2 were purchased from Bioneer (Daejeon, Republic of Korea) and transfected into cells for 48 h using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer. miRNA microarray analysis Total RNA was dephosphorylated and ligated with pCp-Cy3 mononucleotide and the labeled samples were hybridized with a miRNA Microarray (15K, Agilent Technologies Inc., Palo Alto, CA, USA) using a miRNA Labeling Reagent and Hybridization kit (Agilent). The arrays were then washed and immediately imaged using Agilent's DNA microarray scanner and quantified with Feature Extraction Software (Agilent). Data normalization and the selection of fold-changed genes were performed using GeneSpringGX 7.3 (Agilent). The averages of normalized ratios were calculated by dividing the average of the normalized signal channel intensity by the average of the normalized control channel intensity.
qRT-PCR To evaluate the miRNAs expression level, total RNA was used for reverse transcription (RT) reactions and qRT-PCR was performed on the LightCycler 480 and DNA SYBR Green I Master (Roche Diagnostic, Mannheim, Germany) according to the manufacturer's protocol. The cycle number at which the product level exceeded an arbitrarily chosen threshold (CT) was determined for each target sequence, and the amount of each miRNA relative to control RNA was described using the formula 2 À DCT , where
The plasmid containing 3 0 UTRs for ZEB1 (pCI-neo-hRL35) was kindly donated by Goodall. 26 Cells were seeded onto 24-well plates and co-transfected with reporter plasmid and pGL3-control (for normalization; Promega, Madison, WI, USA) for 24 h. The luciferase activity was then measured using a GloMax Luminometer (Promega) according to the manufacturer's instructions. The expression of firefly and Renilla luciferase was measured sequentially from a single sample and the activity of each promoter was obtained directly by the ratio of Renilla to firefly luciferase.
miRNA 3
0 UTR of ZEB2 assay
The plasmid containing 3 0 UTRs for ZEB2 (pMIR-REPORT, Ambion, Austin, TX, USA) was described previously. 9 Cells were co-transfected with the reporter and Renilla-luciferase plasmids for 24 h and the luciferase activity was measured as above. The expression of firefly and Renilla luciferase was measured sequentially from a single sample and the activity of each promoter was obtained directly by the ratio of firefly to Renilla luciferase. pMIR-REPORT luciferase plasmid with cytomegalovirus promoter was used as a control. The data from the luciferase experiments were then compared with the activity of the control vector.
Mutagenesis of luciferase construct
Site-directed mutagenesis was performed using a Dokdo Site-Specific Mutagenesis Kit (ELPIS-Biotech, Daejeon, Korea) to mutate base pair 7 in the predicted seed region that was targeted by miR-205 in the target 3 0 UTR. For the modification of the seed region, the following primer set was used: RL-ZEB1 construct; forward, 5 0 -GAATATGTGGTAACATCGACCTAATAT GACATGAAGCTTTGTATCT-3 0 and reverse, 5 0 -AGATACAAAGCTTCATGTCAT ATTAGGTCGATGTTACCACATATTC-3 0 , pMIR-ZEB1 construct; forward, 5 0 -TCT TAAAGTGACCTGGACCCACCTTAAAAAGTAAGATGAGAA-3 0 and reverse, 5 0 -TTCTCATCTTACTTTTTAAGGTGGGTCCAGGTCACTTTAAGA-3 0 .
Luciferase reporter assay
The proximal promoter of miR-205 was generated by PCR from human genomic DNA and cloned into a pGL3 vector. The wild-type and E-box mutant E-cadherin promoter constructs were purchased from Addgene (Cambridge, MA, USA). Cells were seeded in a 12-well plate and transfected with the reporter construct and a b-galactosidase expression vector for 24 h. A luciferase reporter assay was then performed using a Luciferase Assay system (Promega) as previously described. 43 The luciferase activity, expressed as relative light units, was normalized by b-galactosidase activity.
ChIP assay A ChIP assay was performed according to the manufacturer's instructions (Upstate Biotechnology, Lake Placid, NY, USA). The DNA isolated through the ChIP reactions was subjected to PCR using primers specific to the miR-205 proximal promoter (region A, as previously described; 27 Immunoblotting Cells were lysed in radioimmunoprecipitation assay buffer and the lysates were subjected to immunoblotting as previously described. 23 The antibodies used for immunoblotting were Mel-18, DNMT1, DNMT3a, DNMT3b, ZEB1 and ZEB2 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); N-cadherin, vimentin and fibronectin from Abcam (Cambridge, UK); E-cadherin and b-catenin from BD Biosciences (Palo Alto, CA, USA); and b-actin from Sigma-Aldrich.
Confocal microscopy
Cells were seeded on coverslips (Lab-Tek II Chamber Slide System, Nalge Nunc International, Rochester, NY, USA), fixed with methanol for 30 min at room temperature, and permeabilized with 0.1% Triton X-100 followed by several washes in phosphate-buffered saline with 3% bovine serum albumin. Cells were then incubated with primary antibodies overnight at 4 1C and further reacted with Alexa Fluor 488-goat anti-rabbit immunoglobin G (IgG) antibody (1:500, Molecular Probes, Eugene, OR, USA) or Alexa Fluor 594-goat anti-mouse IgG antibody (1:500, Molecular Probes) for 1 h at room temperature. The final samples were mounted onto slides and visualized using a Zeiss Axiophot confocal microscope.
Reverse transcription-PCR
Total RNA was isolated and reverse transcription-PCR was performed as previously described. 23 The following specific primers were used for the PCR reaction: Mel-18, Transwell migration assay Cells were plated in the upper chamber of a transwell assay (Neuro Probe, Inc., Gaithersburg, MD, USA) and allowed to migrate to the lower chamber for 15 h. The transwell membranes were then fixed and stained using a Diff Quik staining kit (Sysmex, Kobe, Japan). Membranes were removed from the transwells and cells on the undersurface of the Millipore membrane (EMD Millipore Corporation, Billerica, MA, USA) were counted under a light microscope (average of five semi-random non-overlapping fields at Â 200 magnification).
Invasion assay
Cells were added to the upper compartments of BioCoat Matrigel Invasion Chambers (BD Biosciences). After 24 h, cells on the upper surface of the filters were removed with a cotton swab and invading cells present in the lower surface were fixed and stained with a Diff Quik staining kit. Cells on the undersurface of the Millipore membrane were counted as above.
Immunohistochemistry
Frozen sections from tumors in NOD/SCID mice previously injected with control or Mel-18 knockdown MCF-7 cells 24 were used for detection of the expression of EMT-related molecules by immunochemistry. The immunochemistry was performed as previously described. 24, 44 
